Project Grant R43CA281633
Award Date 9/19/23
Completion Date 8/31/24
Dollars Obligated $388K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- This $400,000 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Expression Therapeutics, Inc. in Tucker, GA supports the development of allogeneic cell and gene therapy for neuroendocrine tumors (NETs). NETs are a rare type of cancer with an increasing incidence in the U.S., for which there are currently limited curative treatment options beyond surgical resection in some cases. The project aims to advance innovative cell and gene therapy...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on developing novel therapeutic approaches to treat neuroblastoma, the most common extracranial solid pediatric cancer and a leading cause of cancer-related deaths in children. The $690,013 award to Pennsylvania State University's Milton S. Hershey Medical Center aims to target the role of extracellular vesicles (EVs) in neuroblastoma progression and metastasis. Specifically, the...
- This federal Project Grant award in the amount of $767,328.00 was provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to St. Jude Children's Research Hospital Inc. to support research aimed at developing a novel therapeutic approach for treating neuroblastoma, a deadly childhood cancer. The key focus of this 5-year project is to investigate the efficacy of combining chemotherapy and immunotherapy with the drug indisulam, which selectively degrades the splicing...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma (liver cancer). The $470,759 award, commencing on September 1, 2025, aims to prevent CAR T-cell exhaustion and improve the antitumor activity of GPC3-CAR T-cells through the precise, on-demand control...
- This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...
- This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
- This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 - Cancer Treatment Research to St. Jude Children's Research Hospital Inc. for $768,713 on August 1, 2025. The funding supports research to dissect how the EP300 and CBP histone acetyltransferase proteins control cell state-specific phenotypes and chemosensitivity in high-risk neuroblastoma. The objectives are to capitalize on transcriptional control to identify mechanism-based, targeted cancer therapies that can...